A new biotech out of Dana-Farber wants to join the long non-coding RNA party, with help from Bob Langer

Biotechs focusing on long non-coding RNAs have proliferated in recent years, and another new company announced its launch early Tuesday.

NextRNA Therapeutics came out of stealth with $56 million in financing — $9.3 million from a seed financing and $46.8 million from a Series A — as it looks to join the increasingly crowded “lncRNA” biotech space.